Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 299-306

  Powles, Trevor J ^a   Diem, Susan J ^b   Fabian, Carol J ^c   Neven, Patrick ^d   Wickerham, D Lawrence ^e   Cox, David A ^f   Muram, David ^f   Agnusdei, Donato ^f   Dowsett, Sherie A ^f   Amewou Atisso, Messan ^f   Cummings, Steven R ^g  

^a Cancer Centre London at Parkside   (United Kingdom)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e NSABP Foundation Inc   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arzoxifene; Breast cancer prevention; Clinical trial; Selective estrogen receptor modulator (SERM)

Indexed keywords

ARZOXIFENE; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL EXAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; MUSCLE CRAMP; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PIPERIDINES; POSTMENOPAUSE; RISK FACTORS; THIOPHENES;

EID: 84863988334     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2041-5     Document Type: Article

References (25)

1. B Fisher JP Costantino DL Wickerham, et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371 1388 9747868 10.1093/jnci/90.18. 1371 1:CAS:528:DyaK1cXmtlelurs%3D
2. U Veronesi P Maisonneuve A Costa, et al. 1998 Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study Lancet 352 93 97 9672273 1:CAS:528:DyaK1cXkvVehtrc%3D
3. T Powles R Eeles S Ashley, et al. 1998 Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Lancet 352 98 101 9672274 1:CAS:528:DyaK1cXkvVeht7w%3D
4. J Cuzick J Forbes R Edwards, et al. 2002 First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial Lancet 360 817 824 12243915 10.1016/S0140-6736(02)09962-2 1:CAS:528:DC%2BD38XntVWmsrg%3D
5. B Ettinger DM Black BH Mitlak, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645 10517716 10.1001/jama.282.7.637 1:CAS:528:DyaK1MXlvVKqurg%3D
6. SR Cummings S Eckert KA Krueger, et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. [see comment] [erratum appears in JAMA 1999;282(22):2124] JAMA 281 2189 2197 10376571 10.1001/jama.281.23.2189 1:CAS:528:DyaK1MXktFGitL0%3D
7. S Martino J Costantino M McNabb, et al. 2004 The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials Oncologist 9 116 125 15047916 10.1634/theoncologist.9-2-116 1:CAS:528:DC%2BD2cXjslWnsb0%3D
8. VG Vogel JP Costantino DL Wickerham, et al. 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes JAMA 295 2727 2741 16754727 10.1001/jama.295.23.joc60074 1:CAS:528:DC%2BD28XmtFOltLc%3D
9. SR Cummings K Ensrud PD Delmas, et al. 2010 Lasofoxifene for postmenopausal women with osteoporosis N Engl J Med 362 686 696 20181970 10.1056/NEJMoa0808692 1:CAS:528:DC%2BC3cXisFOqsro%3D
10. A La Croix TJ Powles CK Osborn, et al. 2010 Breast cancer incidence in the PEARL trial of lasofoxifene in postmenopausal osteoporotic women J Natl Cancer Inst 102 1706 1715 10.1093/jnci/djq415
11. SL Silverman C Christiansen HK Genant, et al. 2008 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923 1934 18665787 10.1359/jbmr.080710 1:CAS:528:DC%2BD1MXosVylsbo%3D
12. DF Archer JV Pinkerton WH Utian, et al. 2009 Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women Menopause 16 1109 1115 19543129 10.1097/gme.0b013e3181a818db
13. N Suh AL Glasebrook AD Palkowitz, et al. 2001 Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer Cancer Res 61 8412 8415 11731420 1:CAS:528:DC%2BD3MXptFCktLY%3D
14. AD Palkowitz AL Glasebrook KJ Thrasher KL Hauser, et al. 1998 Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4- hydroxyphenyl)]benzothiophene: a novel, highly potent, selective estrogen receptor modulator J Med Chem 40 1407 1416 10.1021/jm970167b
15. M Sato CH Turner T Wang MD Adrian, et al. 1998 LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo J Pharmacol Exp Ther 287 1 7 9765314 1:CAS:528:DyaK1cXmvVSqt7k%3D
16. A Buzdar JA O'Shaughnessy DJ Booser, et al. 2003 Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer J Clin Oncol 21 1007 1014 12637464 10.1200/JCO.2003.06.108 1:CAS:528:DC%2BD2cXpsVGqsLc%3D
17. J Baselga A Llombart-Cussac M Bellet, et al. 2003 Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients Ann Oncol 14 1383 1390 12954577 10.1093/annonc/mdg368 1:STN:280:DC%2BD3svhsFSjsw%3D%3D
18. V Deshmane S Krishnamurthy AS Melemed P Peterson AU Buzdar 2007 Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer J Clin Oncol 25 4967 4973 17971595 10.1200/JCO.2006.09.5992 1:CAS:528:DC%2BD2sXhtlOhtbfK
19. CJ Fabian BF Kimler J Anderson, et al. 2004 Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator Clin Cancer Res 10 5403 5417 15328178 10.1158/1078-0432.CCR-04-0171 1:CAS:528:DC%2BD2cXmvFSltL8%3D
20. SR Cummings M McClung JY Reginster, et al. 2011 Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women J Bone Miner Res 26 397 404 20658564 10.1002/jbmr.191 1:CAS:528:DC%2BC3MXjt1Wqs78%3D
21. MH Gail LA Brinton DP Byar, et al. 1989 Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1879 1886 2593165 10.1093/jnci/81.24. 1879 1:STN:280:DyaK3c%2FnvF2kuw%3D%3D
22. J Cuzick T Powles U Veronesi, et al. 2003 Overview of the main outcomes in breast-cancer prevention trials Lancet 361 296 300 12559863 10.1016/S0140-6736(03)12342-2 1:STN:280:DC%2BD3s%2FltVCmsA%3D%3D
23. VG Vogel JP Costantino DL Wickerham, et al. 2010 Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer Cancer Prev Res 3 696 706 10.1158/1940-6207.CAPR-10-0076 1:CAS:528:DC%2BC3cXht1Gju7zP
24. J Cuzick JF Forbes I Sestak, et al. 2007 Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial J Natl Cancer Inst 99 272 282 17312304 10.1093/jnci/djk049 1:CAS:528: DC%2BD2sXjsVeitrs%3D
25. TJ Powles S Ashley A Tidy, et al. 2007 Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial J Natl Cancer Inst 99 283 290 17312305 10.1093/jnci/djk050 1:CAS:528: DC%2BD2sXjsVeitrg%3D